Top Story

Bevacizumab-induced hypertension associated with improved OS, PFS in glioblastoma

January 27, 2015

Patients with recurrent glioblastoma who experienced bevacizumab-induced hypertension demonstrated prolonged OS and PFS, according to study results.

The findings suggest bevacizumab-induced hypertension may be a marker of outcome in this patient population, researchers wrote.

Kate Nathanson In the Journals

ATRX mutation possible biomarker for rare neuroendocrine tumors

January 22, 2015
A somatic mutation in the ATP-dependent helicase, or ATRX,  gene — recently demonstrating potential as a molecular marker for aggressive brain tumors…
In the Journals

IG-IMRT showed favorable outcomes in skull base chordoma, chondrosarcoma

January 19, 2015
Patients with chordomas or chondrosarcomas of the skull base had favorable 5-year OS and local control after high-dose image-guided intensity-modulated radiation…
FDA News

FDA grants orphan drug, rare pediatric disease status to entrectinib for neuroblastoma

December 29, 2014
The FDA has granted both orphan drug designation and rare pediatric disease designation to entrectinib for the treatment of neuroblastoma, according to the drug’s…
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »

Filter By:

In the Journals

Bevacizumab-induced hypertension associated with improved OS, PFS in glioblastoma

January 27, 2015
Patients with recurrent glioblastoma who experienced bevacizumab-induced hypertension demonstrated prolonged OS and PFS, according to study…
Kate Nathanson In the Journals

ATRX mutation possible biomarker for rare neuroendocrine tumors

January 22, 2015
A somatic mutation in the ATP-dependent helicase, or ATRX,  gene — recently demonstrating potential as a molecular marker for…
In the Journals

IG-IMRT showed favorable outcomes in skull base chordoma, chondrosarcoma

January 19, 2015
Patients with chordomas or chondrosarcomas of the skull base had favorable 5-year OS and local control after high-dose image-guided…
FDA News

FDA grants orphan drug, rare pediatric disease status to entrectinib for neuroblastoma

December 29, 2014
The FDA has granted both orphan drug designation and rare pediatric disease designation to entrectinib for the treatment of neuroblastoma, according…
In the Journals

Sunitinib appeared active in meningioma

December 23, 2014
Sunitinib appeared effective in patients with recurrent atypical and malignant meningioma, according to results of a prospective, multicenter, phase…
In the Journals

Hospice care reduced end-of-life costs, hospitalizations for Medicare beneficiaries

November 11, 2014
Medicare beneficiaries with poor-prognosis cancers who received hospice care had lower health care costs at the end of life, according to study…
FDA News

FDA grants orphan drug status to DNX-2401 for glioma treatment

October 9, 2014
DNAtrix Inc. recently announced that the FDA has granted orphan drug designation to DNX-2401 for the treatment of malignant glioma.DNX-2401 — a…
FDA News

FDA grants aldoxorubicin orphan drug status

October 1, 2014
CytRx Corp. announced that the FDA granted multiple orphan drug designation to aldoxorubicin for the treatment of patients with glioblastoma…
Craig Horbinski, MD In the Journals

Web-based app predicted mutation probability in gliomas

September 26, 2014
A novel interactive Web-based application appears to have utility in accurately identifying IDH1/2 mutation probability in gliomas, according to…
In the Journals

Primary tumor site affected clinical features, outcomes in pediatric neuroblastoma

September 19, 2014
Tumor features and outcomes varied considerably by primary tumor site among children with neuroblastoma, according to study results.Kieuhoa T. Vo
More Headlines »
morganatic-roan
morganatic-roan